The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Breakthrough Therapy (BT) Designation Market Research Report 2024

Global Breakthrough Therapy (BT) Designation Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1885991

No of Pages : 108

Ask Your Query
Synopsis
The global Breakthrough Therapy (BT) Designation market was valued at US$ 53250 million in 2023 and is anticipated to reach US$ 94060 million by 2030, witnessing a CAGR of 8.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Breakthrough Therapy (BT) Designation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Breakthrough Therapy (BT) Designation.
Report Scope
The Breakthrough Therapy (BT) Designation market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Breakthrough Therapy (BT) Designation market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Breakthrough Therapy (BT) Designation companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Abbvie
Novartis International AG
Janssen
BMS
Eli Lilly
Gilead
Sanofi
Regeneron
Acadia
Boehringer Ingelheim
Amgen
AstraZeneca
GlaxoSmithKline
Vertex
Alexion
Merck
Jazz Pharmaceuticals
Exelixis
Eisai
Takeda
Pfizer
Segment by Type
Oncology
Infectious Diseases
Rare Diseases
Autoimmune Diseases
Pulmonary Diseases
Neurological Disorders
Others
Segment by Application
Hospital
Clinic
Research Institute
Laboratories
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Breakthrough Therapy (BT) Designation companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Breakthrough Therapy (BT) Designation Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oncology
1.2.3 Infectious Diseases
1.2.4 Rare Diseases
1.2.5 Autoimmune Diseases
1.2.6 Pulmonary Diseases
1.2.7 Neurological Disorders
1.2.8 Others
1.3 Market by Application
1.3.1 Global Breakthrough Therapy (BT) Designation Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Institute
1.3.5 Laboratories
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Breakthrough Therapy (BT) Designation Market Perspective (2019-2030)
2.2 Breakthrough Therapy (BT) Designation Growth Trends by Region
2.2.1 Global Breakthrough Therapy (BT) Designation Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Breakthrough Therapy (BT) Designation Historic Market Size by Region (2019-2024)
2.2.3 Breakthrough Therapy (BT) Designation Forecasted Market Size by Region (2025-2030)
2.3 Breakthrough Therapy (BT) Designation Market Dynamics
2.3.1 Breakthrough Therapy (BT) Designation Industry Trends
2.3.2 Breakthrough Therapy (BT) Designation Market Drivers
2.3.3 Breakthrough Therapy (BT) Designation Market Challenges
2.3.4 Breakthrough Therapy (BT) Designation Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Breakthrough Therapy (BT) Designation Players by Revenue
3.1.1 Global Top Breakthrough Therapy (BT) Designation Players by Revenue (2019-2024)
3.1.2 Global Breakthrough Therapy (BT) Designation Revenue Market Share by Players (2019-2024)
3.2 Global Breakthrough Therapy (BT) Designation Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Breakthrough Therapy (BT) Designation Revenue
3.4 Global Breakthrough Therapy (BT) Designation Market Concentration Ratio
3.4.1 Global Breakthrough Therapy (BT) Designation Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Breakthrough Therapy (BT) Designation Revenue in 2023
3.5 Breakthrough Therapy (BT) Designation Key Players Head office and Area Served
3.6 Key Players Breakthrough Therapy (BT) Designation Product Solution and Service
3.7 Date of Enter into Breakthrough Therapy (BT) Designation Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Breakthrough Therapy (BT) Designation Breakdown Data by Type
4.1 Global Breakthrough Therapy (BT) Designation Historic Market Size by Type (2019-2024)
4.2 Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Type (2025-2030)
5 Breakthrough Therapy (BT) Designation Breakdown Data by Application
5.1 Global Breakthrough Therapy (BT) Designation Historic Market Size by Application (2019-2024)
5.2 Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Breakthrough Therapy (BT) Designation Market Size (2019-2030)
6.2 North America Breakthrough Therapy (BT) Designation Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Breakthrough Therapy (BT) Designation Market Size by Country (2019-2024)
6.4 North America Breakthrough Therapy (BT) Designation Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Breakthrough Therapy (BT) Designation Market Size (2019-2030)
7.2 Europe Breakthrough Therapy (BT) Designation Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Breakthrough Therapy (BT) Designation Market Size by Country (2019-2024)
7.4 Europe Breakthrough Therapy (BT) Designation Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size (2019-2030)
8.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region (2019-2024)
8.4 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Breakthrough Therapy (BT) Designation Market Size (2019-2030)
9.2 Latin America Breakthrough Therapy (BT) Designation Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Breakthrough Therapy (BT) Designation Market Size by Country (2019-2024)
9.4 Latin America Breakthrough Therapy (BT) Designation Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size (2019-2030)
10.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country (2019-2024)
10.4 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Breakthrough Therapy (BT) Designation Introduction
11.1.4 Roche Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Abbvie
11.2.1 Abbvie Company Detail
11.2.2 Abbvie Business Overview
11.2.3 Abbvie Breakthrough Therapy (BT) Designation Introduction
11.2.4 Abbvie Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.2.5 Abbvie Recent Development
11.3 Novartis International AG
11.3.1 Novartis International AG Company Detail
11.3.2 Novartis International AG Business Overview
11.3.3 Novartis International AG Breakthrough Therapy (BT) Designation Introduction
11.3.4 Novartis International AG Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.3.5 Novartis International AG Recent Development
11.4 Janssen
11.4.1 Janssen Company Detail
11.4.2 Janssen Business Overview
11.4.3 Janssen Breakthrough Therapy (BT) Designation Introduction
11.4.4 Janssen Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.4.5 Janssen Recent Development
11.5 BMS
11.5.1 BMS Company Detail
11.5.2 BMS Business Overview
11.5.3 BMS Breakthrough Therapy (BT) Designation Introduction
11.5.4 BMS Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.5.5 BMS Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Detail
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Breakthrough Therapy (BT) Designation Introduction
11.6.4 Eli Lilly Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.6.5 Eli Lilly Recent Development
11.7 Gilead
11.7.1 Gilead Company Detail
11.7.2 Gilead Business Overview
11.7.3 Gilead Breakthrough Therapy (BT) Designation Introduction
11.7.4 Gilead Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.7.5 Gilead Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Breakthrough Therapy (BT) Designation Introduction
11.8.4 Sanofi Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.8.5 Sanofi Recent Development
11.9 Regeneron
11.9.1 Regeneron Company Detail
11.9.2 Regeneron Business Overview
11.9.3 Regeneron Breakthrough Therapy (BT) Designation Introduction
11.9.4 Regeneron Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.9.5 Regeneron Recent Development
11.10 Acadia
11.10.1 Acadia Company Detail
11.10.2 Acadia Business Overview
11.10.3 Acadia Breakthrough Therapy (BT) Designation Introduction
11.10.4 Acadia Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.10.5 Acadia Recent Development
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Detail
11.11.2 Boehringer Ingelheim Business Overview
11.11.3 Boehringer Ingelheim Breakthrough Therapy (BT) Designation Introduction
11.11.4 Boehringer Ingelheim Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.11.5 Boehringer Ingelheim Recent Development
11.12 Amgen
11.12.1 Amgen Company Detail
11.12.2 Amgen Business Overview
11.12.3 Amgen Breakthrough Therapy (BT) Designation Introduction
11.12.4 Amgen Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.12.5 Amgen Recent Development
11.13 AstraZeneca
11.13.1 AstraZeneca Company Detail
11.13.2 AstraZeneca Business Overview
11.13.3 AstraZeneca Breakthrough Therapy (BT) Designation Introduction
11.13.4 AstraZeneca Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.13.5 AstraZeneca Recent Development
11.14 GlaxoSmithKline
11.14.1 GlaxoSmithKline Company Detail
11.14.2 GlaxoSmithKline Business Overview
11.14.3 GlaxoSmithKline Breakthrough Therapy (BT) Designation Introduction
11.14.4 GlaxoSmithKline Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.14.5 GlaxoSmithKline Recent Development
11.15 Vertex
11.15.1 Vertex Company Detail
11.15.2 Vertex Business Overview
11.15.3 Vertex Breakthrough Therapy (BT) Designation Introduction
11.15.4 Vertex Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.15.5 Vertex Recent Development
11.16 Alexion
11.16.1 Alexion Company Detail
11.16.2 Alexion Business Overview
11.16.3 Alexion Breakthrough Therapy (BT) Designation Introduction
11.16.4 Alexion Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.16.5 Alexion Recent Development
11.17 Merck
11.17.1 Merck Company Detail
11.17.2 Merck Business Overview
11.17.3 Merck Breakthrough Therapy (BT) Designation Introduction
11.17.4 Merck Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.17.5 Merck Recent Development
11.18 Jazz Pharmaceuticals
11.18.1 Jazz Pharmaceuticals Company Detail
11.18.2 Jazz Pharmaceuticals Business Overview
11.18.3 Jazz Pharmaceuticals Breakthrough Therapy (BT) Designation Introduction
11.18.4 Jazz Pharmaceuticals Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.18.5 Jazz Pharmaceuticals Recent Development
11.19 Exelixis
11.19.1 Exelixis Company Detail
11.19.2 Exelixis Business Overview
11.19.3 Exelixis Breakthrough Therapy (BT) Designation Introduction
11.19.4 Exelixis Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.19.5 Exelixis Recent Development
11.20 Eisai
11.20.1 Eisai Company Detail
11.20.2 Eisai Business Overview
11.20.3 Eisai Breakthrough Therapy (BT) Designation Introduction
11.20.4 Eisai Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.20.5 Eisai Recent Development
11.21 Takeda
11.21.1 Takeda Company Detail
11.21.2 Takeda Business Overview
11.21.3 Takeda Breakthrough Therapy (BT) Designation Introduction
11.21.4 Takeda Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.21.5 Takeda Recent Development
11.22 Pfizer
11.22.1 Pfizer Company Detail
11.22.2 Pfizer Business Overview
11.22.3 Pfizer Breakthrough Therapy (BT) Designation Introduction
11.22.4 Pfizer Revenue in Breakthrough Therapy (BT) Designation Business (2019-2024)
11.22.5 Pfizer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock